Emerging Promise of Nanoparticle-Based Treatment for Parkinson’s disease
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Neurodegenerative disorders are consequences of the deterioration of cells and tissues with a mature undesirable way of life. The degenerative disease like Parkinson's disease (PD) influences Central nervous systems (CNS) and cardiovascular systems. In this study, we show Parkinson's disease combined with rising nanoparticles, draw hopeful methodologies for improving medication transport to the scattered CNS, and examine their suggestions for clinical practice. A search strategy was designed in order to identify articles published in the high ranking journals. All the search results from the prominent databases, namely Scopus, Springer, PubMed, Cochrane, and ScienceDirect, were collected, and all possible duplicates were discarded. The worse condition must be overcome by traditional treatment systems. Nanotechnology and nanoparticles based methodology medical transport systems could reverse the treatment of Parkinson's disease. Dopamine consumption in the striatum is the sign of PD and its creation forms. Still, the pathophysiology of the parkinsonian side effects and especially parkinsonian trembles are under discussion. Parkinson's disease alarms genuine anxiety because of its consequences for the personal satisfaction of patients and its burden to social prescriptions and treatments that have risen for the management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Freeze-drying of nanoparticles: Formulation, process and storage considerations
ABDELWAHED, W., DEGOBERT, G., STAINMESSE, S., & FESSI, H. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.017 · Cited by 1,611
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States
Mattson, M. P., & Arumugam, T. V. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.011 · Cited by 1,242
Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology
Simon, D. K., Tanner, C. M., & Brundin, P. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.08.002 · Cited by 1,114
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733
Wearable Assistant for Parkinson’s Disease Patients With the Freezing of Gait Symptom
Bachlin, M., Plotnik, M., Roggen, D., Maidan, I., Hausdorff, J. M., Giladi, N., & Troster, G. (2010) · IEEE Transactions on Information Technology in Biomedicine · doi:10.1109/titb.2009.2036165 · Cited by 693
The current and projected economic burden of Parkinson's disease in the United States
Kowal, S. L., Dall, T. M., Chakrabarti, R., Storm, M. V., & Jain, A. (2013) · Movement Disorders · doi:10.1002/mds.25292 · Cited by 667
Cited by
An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases
Teleanu, D. M., Niculescu, A.-G., Lungu, I. I., Radu, C. I., Vladâcenco, O., Roza, E., Costăchescu, B., Grumezescu, A. M., & Teleanu, R. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115938 · Cited by 1,085
“, 5%) in people over 80 years old [1,13,21,22].”
BackgroundTeleanu, R. I., Niculescu, A.-G., Roza, E., Vladâcenco, O., Grumezescu, A. M., & Teleanu, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115954 · Cited by 596
The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation
Rahman, M. M., Islam, F., -Or-Rashid, M. H., Mamun, A. A., Rahaman, M. S., Islam, M. M., Meem, A. F. K., Sutradhar, P. R., Mitra, S., Mimi, A. A., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.903570 · Cited by 253
Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier
Teleanu, R. I., Preda, M. D., Niculescu, A.-G., Vladâcenco, O., Radu, C. I., Grumezescu, A. M., & Teleanu, D. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050987 · Cited by 200
Sharma, R., Singla, R. K., Banerjee, S., Sinha, B., Shen, B., & Sharma, R. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104795 · Cited by 81
Metadata
- Venue
- Biointerface Research in Applied Chemistry
- Publisher
- AMG Transcend Association
- Published
- 2020-06-07
- Volume
- 10
- Issue
- 6
- Pages
- 7135-7151
- ISSN
- 2069-5837 (ISSN-L)
- OpenAlex
- W4238619351
- Cited by
- 36
- References
- 28
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging Promise of Nanoparticle-Based Treatment for Parkinson’s disease. https://app.cochat.ai/papers/10.33263/briac106.71357151
- The paper
- Emerging Promise of Nanoparticle-Based Treatment for Parkinson’s disease. (2020). Biointerface Research in Applied Chemistry. https://doi.org/10.33263/briac106.71357151
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.